Alaunos Announces Lower Liver Weight After Fat Adjustment in ALN1003 Study
Alaunos Therapeutics reported new preclinical data showing ALN1003 treatment resulted in lower liver weight after adjusting for body fat percentage in a 48-day diet-induced obesity study. This finding supports the efficacy hypothesis of ALN1003 and aligns with previous results showing reduced liver injury markers and improved insulin resistance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day